Press release: Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Ncardia Acquires STAR-CRISPR Technology for Advanced Gene Editing of iPSCs
Unveiling Ncardia's Path to Innovation and Growth
The Urgent Need for Reliable Cell Models in ALS Research
Ncardia's Remarkable Journey in 2023
.png)
Ncardia Welcomes Divisional CEO, Dr. Jeroen de Groot
Subscribe to our newsletter
Stay up to date on iPSC innovations, events and news.
